Mereo BioPharma
MREO
80 hedge funds and large institutions have $277M invested in Mereo BioPharma in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 11 closing their positions.
163% more call options, than puts
Call options by funds: $2.63M | Put options by funds: $1M
155% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 11
100% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 12
53% more capital invested
Capital invested by funds: $182M → $277M (+$95.7M)
25% more funds holding
Funds holding: 64 → 80 (+16)
0.77% more ownership
Funds ownership: 11.21% → 11.98% (+0.77%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$22.6M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$17.3M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.89M |
| 4 |
Morgan Stanley
New York
|
+$4.16M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$24.2M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$12.6M |
| 3 |
TC
Tejara Capital
London,
United Kingdom
|
-$4.21M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$2.48M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.8M |
MREO Hedge Fund Activity: Q1 2024 in Review
80 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q1 2024, worth a combined $277M — up 53% from $182M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new MREO positions and 11 closed out — a net gain of 17 holders — while 24 added to existing stakes and 12 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $22.6M. The largest seller was Soleus Capital Management, cutting an estimated $24.2M.
- 80 institutional investors held Mereo BioPharma (MREO) as of Q1 2024, up from 64 in Q4 2023.
- Funds reported $277M of Mereo BioPharma stock for Q1 2024, up 53% quarter-over-quarter.
- 28 funds opened new Mereo BioPharma positions in Q1 2024 and 11 closed out, a net change of +17 holders.
- The largest Mereo BioPharma buyer in Q1 2024 was Adage Capital Partners, an estimated $22.6M added.
- The largest Mereo BioPharma seller in Q1 2024 was Soleus Capital Management, an estimated $24.2M sold.
Based on aggregated 13F filings for Q1 2024.